0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover0.00%IV-24.38%PremiumSep 20, 2024Expiry Date1.47Intrinsic Value100Multiplier2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.72Leverage Ratio--Theta--Rho--Eff Leverage--Vega
ESSA Pharma Stock Discussion
ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 Esmo Congress
ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO Congress
ESSA Pharma presented updated Phase 1/2 clinical data for masofaniten (EPI-7386) in combination with enzalutamide at the 2024 ESMO Congress. The study focused on patients with metastatic castration-resistant prostate cancer(mCRPC). Key findings include:
- 88% of patients achieved PSA90
- 69% achieved PSA90 in less than 90 days
- 63% achieved PSA <0.2ng/mL
- After 15.2 ...
PR Newswire·
Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC
Across all cohorts of patients including those recently enrolled into cohort four, 81% of patients achieved PSA90, 69% of patients achieved PSA90 in less than 90 days, and 56% of pa...
$ESSA Pharma (EPIX.US)$ saw its stock rise by 22.60% during the previous trading session. This surge in price was accompanied by a notable increase in option volume, which totaled 3.40K. The option market for ESSA Pharma is currently displaying a high l...
No comment yet